Novartis Plans Three NME Filings In 2005, Including First Oral VEGF Inhibitor
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis plans three NME filings in 2005, including first oral VEGF agent, firm says during Jan. 20 R&D day. PTK787 has blockbuster potential in colorectal cancer, Novartis says. Nine more NME filings are scheduled for next two years